Will Trump's generic drug tariffs bring manufacturing back to the US?
by AUSTIN DENEAN | The National News Desk
Wed, July 22, 2026 at 2:52 PM
Medications are stored on shelves at a pharmacy on May 12, 2025 in Los Angeles, California. (Photo by Eric Thayer/Getty Images)
WASHINGTON (TNND) — President Donald Trump said he will soon impose massive tariffs on generic drugs from overseas as he tries to push the pharmaceutical industry to bring its manufacturing back to the United States.
Trump announced the tariffs will start at 100% in August 2028 and increase to 200% in August 2029, a deadline that would come after the end of his term. He has repeatedly threatened sweeping tariffs on imported drugs since returning to office but has not implemented any.
“This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them. The objective of this Policy is to protect the people of the United States,” he wrote.
Generic drugs make up the vast majority of Americans’ prescriptions. But they are primarily manufactured overseas, particularly in India, and rely heavily on China for ingredients. That dependence on foreign suppliers has fueled bipartisan concerns that a geopolitical conflict or supply chain disruption could disrupt access to medications.
But it is also challenging to reshore generic drug manufacturing because companies largely compete on price and make profits on volume.
Truth Social
Donald J. Trump
Verified Account
Truth+ Premium
@realDonaldTrump
· 22h
Effective August 1st, 2026, all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for a two year period of time, after which the TARIFF will be raised to 100% for a one year period of time, and 200% thereafter. This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them. The objective of this Policy is to protect the people of the United States. The Policy on Patented, Branded, or Innovative Drugs, which has been so successful, will remain as is. Pharmaceutical Facilities are being built, at a level never seen before, all over the United States of America. Thank you for your attention to this matter! President DONALD J. TRUMP
Show More
1.09k
4.5k
17.2k
Industry analysts said many generic drugmakers have limited room to absorb tariffs as large as what Trump proposed. Manufacturers would be presented a choice between absorbing the costs, passing them onto consumers, investing large sums to create or expand their U.S. footprint, or exiting the American market entirely.
The administration has released few details beyond the tariff rates and implementation dates, leaving questions about which products would be covered, whether exemptions will be available and whether companies have enough certainty to justify major investments in new U.S. factories.
“This brings capacity manufacturing capacity back into the United States, and there's going to be firms that are going to be able to do it,” said Rena Conti, an associate professor at Boston University’s Questrom School of Business who researches the pharmaceutical industry. “But on the on the flip side, there are drugs that are really only made external to the United States by pretty low-cost producers and exits from the U.S. market can create conditions for shortage or will push people to use much more expensive brands.”
Generic drugmakers typically operate on lower profit margins than their brand-name counterparts because they don’t sell medicines until patents expire and compete against multiple manufacturers offering the same product. The increased costs through tariffs or trying to expand production within the U.S. may be especially difficult for smaller companies that have limited market share or make most of their sales in low-margin drugs.
Trump’s proposal also raises questions about how it will impact drug prices. While the administration argues expanding domestic manufacturing will strengthen long-term supply chains, analysts say tariffs could increase prices or worsen shortages in the near term if manufacturers cannot absorb the added costs.
“Having more investment in American in resilient supply of generics is absolutely mission critical for the U.S.,” Conti said. “But threatening firms and countries with very significant tariffs without a consistent on ramp for investment is not necessarily the best way of getting of getting serious investment.”
The generic drug proposal is the latest move Trump has made to pressure the pharmaceutical industry to increase their footprint in the U.S.
The president has wielded tariffs to push drugmakers to bring more manufacturing back within the U.S. and to lower prices for brand-name drugs. Most of the biggest brand-name manufacturers have announced plans to invest in U.S.-based factories as part of deals with the White House, but few generic drugmakers have done the same.
Bringing down the cost of prescription drugs has been a priority for Trump since he returned to office and one of the primary ways the administration has tried to tackle the affordability issues facing the country.
Trump said his policy on branded drugs will continue. Those agreements tied drug prices charged in the U.S. to cheaper ones abroad as part of the president’s “most favored nation” policy and exempted companies from tariffs for three years.
“Pharmaceutical Facilities are being built, at a level never seen before, all over the United States of America,” Trump said in his post.
The administration has argued the president’s expansive use of tariffs will push more companies across sectors to manufacture more goods in the United States. Similar announcements have led to announcements of expansions for automakers, semiconductors and other industries, though many have included previously announced funds for projects.
Analysts said the threat of tariffs may be a starting point for negotiations with generic drug companies after the administration followed a similar playbook with the major brand-name companies.
